EXPRESS MAIL CERTIFICATE

I hereby certify that, on the date indicated above, this paper or

fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the Assistant Commiss

Washington, DC 20231 by "Express Addressee" service

Name (Print)

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR CREDIT ANY EXCESS IN THE FEES DUE WITH THIS DOCUMENT TO OUR **DEPOSIT ACCOUNT NO. 04-0100**

Lustomer No.:

PATENT TRADEMARK OFFICE

Docket No: 4058/1E827US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

e Application of:

Frances H. ARNOLD, et al.

Serial No.: 09/246,451 Art Unit:

1652

Confirmation No.: 6181

Filed: February 9, 1999

Examiner:

Manjunath N. RAO

For:

APR 0 7 2003

OXYGENASE ENZYMES AND SCREENING METHOD

EXAMINER'S COURTESY COPY OF PENDING CLAIMS

Hon. Commissioner of Patents and Trademarks Washington, DC 20231

April 7, 2003

Sir:

146. (Allowed) A functional cytochrome P450 oxygenase variant comprising a mutation of a glutamic acid residue at a position corresponding to amino acid 331 of cytochrome P450cam from P. putida (SEQ ID NO:2) and having at least 90% sequence identity to SEQ ID NO:2.

{M:\4058\1e827us1\BAR3616.DOC [*40581E827US1*]} Serial No. 09/246,451 Examiner's Courtesy Copy of Pending Claims Response to Office Action dated November 5, 2002

Docket No. 4058/1E827US1

147. (Allowed) The cytochrome P450 oxygenase variant of claim

146, wherein the mutant amino acid at the position corresponding to amino acid

331 is lysine.

148. (Allowed) A functional cytochrome P450 oxygenase variant

comprising at least one mutation of an arginine residue at a position corresponding

to amino acid 280 of cytochrome P450cam from P. putida (SEQ ID NO:2) and having

at least 90% sequence identity to SEQ ID NO:2.

149. (Allowed) The cytochrome P450 oxygenase variant of claim

148, wherein the mutant amino acid at the position corresponding to amino acid

280 is leucine.

150. (Allowed) A functional cytochrome P450 oxygenase variant

comprising at least one mutation of a cysteine residue at a position corresponding

to amino acid 242 of cytochrome P450cam from P. putida (SEQ ID NO:2) and having

at least 90% sequence identity to SEQ ID NO:2.

151. (Allowed) The cytochrome P450 oxygenase variant of claim

148, wherein the mutant amino acid at the position corresponding to amino acid

280 is phenylalanine.

{M:\4058\1e827us1\BAR3616.DOC [*40581E827US1*]} Serial No. 09/246,451

152. (Allowed) A functional cytochrome P450 oxygenase variant comprising at least one mutation at a position selected from the group consisting of

amino acid positions 242, 280, and 331 of SEQ ID NO:2 and having at least 90%

sequence identity to SEQ ID NO:2.

153. (Allowed) The cytochrome P450 oxygenase variant of claim

152 comprising at least one mutation selected from the group consisting of:

(a) a glutamic acid to lysine mutation at position 331 of SEQ

ID NO:2;

(b) an arginine to leucine mutation at position 280 of SEQ ID

NO:2; and

(c) a cysteine to phenylalanine mutation at position 242 of

SEQ ID NO:2.

154. (Allowed) The variant cytochrome P450 oxygenase of claim

152, comprising at least one mutation selected from the group consisting of:

(a) a glutamic acid to arginine or histidine mutation at

position 331 of SEQ ID NO:2; and

(b) an arginine to isoleucine, methionine, or valine mutation

at position 280 of SEQ ID NO:2.

155. (Allowed) A functional oxygenase enzyme variant encoded by a

first polynucleotide that hybridizes to a second polynucleotide under conditions of

high stringency, which second polynucleotide encodes the cytochrome P450

oxygenase enzyme of claim 153.

156. (Twice amended) A cytochrome P450 oxygenase variant having

a catalytic activity at least two times the catalytic activity of wild-type cytochrome

P450_{cam} oxygenase from *P. putida* (SEQ ID NO:2) in promoting the oxygenation of

an oxygenase substrate in the presence of an oxygen donor, at least 90%

sequence identity to SEQ ID NO:2, and a mutation in at least one position

corresponding to one of amino acids 242, 280, and 331 of SEQ ID NO:2.

157. (Twice amended) A cytochrome P450 oxygenase variant having

a catalytic activity at least about ten times the catalytic activity of wild-type

cytochrome P450_{cam} oxygenase from *P. putida* (SEQ ID NO:2) in promoting the

oxygenation of an oxygenase substrate in the presence of an oxygen donor, at

least 90% sequence identity to SEQ ID NO:2, and a mutation in at least one

position corresponding to one of amino acids 242, 280, and 331 of SEQ ID NO:2.

158. (Twice amended) A cytochrome P450 oxygenase variant having

a stability at least two times the stability of wild-type cytochrome P450cam

oxygenase from P. putida (SEQ ID NO:2) in promoting the oxygenation of an

{M:\4058\1e827us1\BAR3616.DOC [*40581E827US1*]} Serial No. 09/246,451

oxygenase substrate in the presence of an oxygen donor, at least 90% sequence

identity to SEQ ID NO:2, and a mutation in at least one position corresponding to

one of amino acids 242, 280, and 331 of SEQ ID NO:2.

159. (Twice amended) A cytochrome P450 oxygenase variant having

a stability at least about ten times the stability of wild-type cytochrome P450cam

oxygenase from P. putida (SEQ ID NO:2) in promoting the oxygenation of an

oxygenase substrate in the presence of an oxygen donor, at least 90% sequence

identity to SEQ ID NO:2, and a mutation in at least one position corresponding to

one of amino acids 242, 280, and 331 of SEQ ID NO:2.

160. (Allowed) A cytochrome P450 oxygenase variant comprising a

sequence selected from the group consisting of SEQ ID NO:11, SEQ ID NO:12, and

SEQ ID NO:13.

161. (Twice amended) An oxygenase variant evolved from a wild-

type oxygenase enzyme, and having a catalytic activity at least ten times the

catalytic activity of the wild-type oxygenase enzyme in promoting the oxygenation

of an oxygenase substrate in the presence of an oxygen donor, which oxygenase

variant was identified by a method comprising the steps of:

{M:\4058\1e827us1\BAR3616.DOC [*40581E827US1*]}

Docket No. 4058/1E827US1

(a) contacting a test enzyme variant with an oxygenase

substrate and the oxygen donor under conditions allowing the formation of an

oxygenated product if said test enzyme variant is an oxygenase enzyme;

(b) providing a coupling enzyme which is capable of

promoting the formation of a detectable composition from the oxygenated product;

(c) detecting the detectable composition; and

(d) selecting any test enzyme having at least 10 times the

catalytic activity of the wild-type oxygenase enzyme in the presence of the oxygen

donor, at least 90% sequence identity to SEQ ID NO:2, and a mutation in at least

one position corresponding to one of amino acids 242, 280, and 331 of SEQ ID

NO:2.

. 6 .

162. The oxygenase variant of claim 161, wherein the detecting of

the detectable composition comprises detection of at least one of ultraviolet light,

color change, fluorescence, and luminescence.

163. The oxygenase variant of claim 161, wherein

(a) the organic substrate is selected from the group

consisting of naphthalene, 3-phenylpropionate, benzene, toluene, benzoic acid,

anthracene, benzphetamine, and coumarin;

(b) the oxygen donor is selected from the group consisting of

hydrogen peroxide and t-butyl peroxide; and

(c) the coupling enzyme is selected from the group

consisting of horseradish peroxidase, cytochrome c peroxidase, tulip peroxidase,

lignin peroxidase, carrot peroxidase, peanut peroxidase, soybean peroxidase, and

NOVOZYME® 502.

e 6 .

164. (Amended) An oxygenase variant evolved from a wild-type

oxygenase enzyme, and having a stability at least ten times the stability of the

wild-type oxygenase enzyme in promoting the oxygenation of an oxygenase

substrate in the presence of an oxygen donor, which oxygenase variant was

identified by a method comprising the steps of:

(a) contacting a test enzyme variant with an oxygenase

substrate and the oxygen donor under conditions allowing the formation of an

oxygenated product if said test enzyme variant is an oxygenase enzyme;

(b) providing a coupling enzyme which is capable of

promoting the formation of a detectable composition from the oxygenated product;

(c) detecting the detectable composition; and

(d) selecting any test enzyme having at least 10 times the

stability of the wild-type oxygenase enzyme, at least 90% sequence identity to

SEQ ID NO:2, and a mutation in at least one position corresponding to at least one

of amino acids 242, 280, and 331 of SEQ ID NO:2.

{M:\4058\1e827us1\BAR3616.DOC [*40581E827US1*]}

Page 7

165. The oxygenase variant of claim 164, wherein the detecting of

the detectable composition comprises detection of at least one of ultraviolet light,

color change, fluorescence, and luminescence.

166. The oxygenase variant of claim 164, wherein

(a) the organic substrate is selected from the group

consisting of naphthalene, 3-phenylpropionate, benzene, toluene, benzoic acid,

anthracene, benzphetamine, and coumarin;

(b) the oxygen donor is selected from the group consisting of

hydrogen peroxide and t-butyl peroxide; and

(c) the coupling enzyme is selected from the group

consisting of horseradish peroxidase, cytochrome c peroxidase, tulip peroxidase,

lignin peroxidase, carrot peroxidase, peanut peroxidase, soybean peroxidase, and

NOVOZYME® 502.

ç 16 ç

167. (Amended) A functional cytochrome P450 oxygenase variant

identified by a method comprising the steps of:

(a) contacting a test cytochrome P450 oxygenase variant

with an oxygenase substrate and an oxygen donor under conditions allowing the

formation of an oxygenated product if said test enzyme variant is an oxygenase

enzyme;

{M:\4058\1e827us1\BAR3616.DOC [*40581E827US1*]} Serial No. 09/246,451 (b) providing a coupling enzyme which is capable of

promoting the formation of a detectable composition from the oxygenated product;

(c) detecting the detectable composition; and

(d) selecting any test enzyme having a mutation at a position

corresponding to at least one of amino acid 331, 280, and 242 of cytochrome

P450cam from P. putida (SEQ ID NO:2) and at least 90% sequence identity to SEQ

ID NO:2.

168. (Allowed) The cytochrome P450 oxygenase variant of claim

167, wherein the detecting of the detectable composition comprises detection of at

least one of ultraviolet light, color change, fluorescence, and luminescence.

169. (Allowed) The cytochrome P450 oxygenase variant of claim

167, wherein

(a) the organic substrate is selected from the group

consisting of naphthalene, 3-phenylpropionate, benzene, toluene, benzoic acid,

anthracene, benzphetamine, and coumarin;

(b) the oxygen donor is selected from the group consisting of

hydrogen peroxide and t-butyl peroxide; and

(c) the coupling enzyme is selected from the group

consisting of horseradish peroxidase, cytochrome c peroxidase, tulip peroxidase,

{M:\4058\1e827us1\BAR3616.DOC [*40581E827US1*]}

lignin peroxidase, carrot peroxidase, peanut peroxidase, soybean peroxidase, and NOVOZYME® 502.

170. (Allowed) The cytochrome P450 variant of claim 146, comprising a mutation at amino acid 331 of SEQ ID NO:2.

171. (Allowed) The cytochrome P450 variant of claim 148, comprising a mutation at amino acid 280 of SEQ ID NO:2.

172. (Allowed) The cytochrome P450 variant of claim 150, comprising a mutation at amino acid 242 of SEQ ID NO:2.

173. (Allowed) The cytochrome P450 variant of claim 152, comprising mutations at amino acids 242, 280, and 331 of SEQ ID NO:2.

175. (Amended) The cytochrome P450 variant of claim 156, comprising at least one mutation selected from lysine at amino acid 331, leucine at amino acid 280, and phenylalanine at amino acid 242.

176. The cytochrome P450 variant of claim 156, wherein the oxygen donor is a peroxide.

177. The cytochrome P450 variant of claim 176, wherein the

peroxide is selected from hydrogen peroxide and t-butyl peroxide.

179. (Amended) The cytochrome P450 variant of claim 157,

comprising at least one mutation selected from lysine at amino acid 331, leucine at

amino acid 280, and phenylalanine at amino acid 242.

180. The cytochrome P450 variant of claim 157, wherein the oxygen

donor is a peroxide.

a * 5

181. The cytochrome P450 variant of claim 180, wherein the

peroxide is selected from hydrogen peroxide and t-butyl peroxide.

183. (Amended) The cytochrome P450 variant of claim 158,

comprising at least one mutation selected from lysine at amino acid 331, leucine at

amino acid 280, and phenylalanine at amino acid 242.

184. The cytochrome P450 variant of claim 158, wherein the oxygen

donor is a peroxide.

185. The cytochrome P450 variant of claim 184, wherein the

peroxide is selected from hydrogen peroxide and t-butyl peroxide.

.

187. (Amended) The cytochrome P450 variant of claim 159,

comprising at least one mutation selected from lysine at amino acid 331, leucine at

amino acid 280, and phenylalanine at amino acid 242.

188. The cytochrome P450 variant of claim 159, wherein the oxygen

donor is a peroxide.

189. The cytochrome P450 variant of claim 184, wherein the

peroxide is selected from hydrogen peroxide and t butyl peroxide.

BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE UNITED STATES PATENT AND TRADEMARK OFFICE

LIMITED RECOGNITION UNDER 37 CFR 10.9(b)

Anna Lovqvist is hereby given limited recognition under 37 CFR. 10.9(b) as an employee of the Darby & Darby P.C. law firm to prepare and prosecute patent applications wherein the patent applicant is the client of the Darby & Darby P.C. law firm, and the attorney or agent of record in the applications is a registered practitioner, located in the United States, who is a member of the Darby & Darby P.C. law firm. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Anna Lovqvist ceases to lawfully reside in the United States, (ii) Anna Lovqvist's employment with the Darby & Darby P.C. law firm ceases or is terminated, or (iii) Anna Lovqvist ceases to remain or reside in the United States on an H1B1 visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the United States Patent and Trademark Office.

Expires: February 4, 2004

Harry I. Moatz

Director of Enrollment and Discipline